AzTrials
AzTrials

Drug or intervention

Multigated Acquisition Scan Clinical Trials

Studies that test Multigated Acquisition Scan, alone, with other treatments or as the comparison.

157 registered studies

In numbers

Open to volunteers
91
Active
137
With results posted
23
All registered
157

Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.

Open to volunteers

All 91
  • Malignant Female Reproductive System Neoplasm, Malignant Solid Neoplasm

    Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

    • Recruiting
    • Age: 18 years and older
    • Phase 2
    • Surgery or procedure

    This phase II ComboMATCH treatment trial compares the effect of neratinib to the combination of neratinib and palbociclib in treating patients with HER2 positive solid tumors.

    Conditions
    Malignant Female Reproductive System Neoplasm, Malignant Solid Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Solid Neoplasm
    Trial name
    NCT06126276
    Testing
    Biopsy Procedure, Biospecimen Collection, Computed Tomography
    Where
    194 sites in United States, Puerto Rico
    Volunteers
    70 people
    Sponsor
    National Cancer Institute (NCI)
  • Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma

    Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

    • Recruiting
    • Age: 18 years and older
    • Phase 2
    • Injection or infusion
    • Surgery or procedure

    This phase II trial compares the effect of sacituzumab govitecan and bevacizumab to standard care (carboplatin, pegylated liposomal doxorubicin, and bevacizumab) in patients with ovarian cancer that has come back after an initial…

    Conditions
    Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma, Recurrent Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Ovarian High Grade Serous Adenocarcinoma
    Trial name
    NCT07504588
    Testing
    Anti-VEGF Monoclonal Antibody, Bevacizumab, Biospecimen Collection
    Where
    22 sites in United States
    Volunteers
    87 people
    Sponsor
    National Cancer Institute (NCI)
  • Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma

    Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

    • Recruiting
    • Age: 18 years and older
    • Phase 3
    • Injection or infusion
    • Surgery or procedure

    This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change…

    Conditions
    Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8
    Trial name
    NCT04181060
    Testing
    Bevacizumab, Biospecimen Collection, Computed Tomography
    Where
    604 sites in United States
    Volunteers
    300 people
    Sponsor
    National Cancer Institute (NCI)
  • Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm

    Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

    • Recruiting
    • Age: 18 to 59 years
    • Phase 2
    • Injection or infusion
    • Surgery or procedure

    This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid…

    Conditions
    Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related
    Trial name
    NCT05554406
    Testing
    Azacitidine, Biospecimen Collection, Bone Marrow Aspiration
    Where
    227 sites in United States, Canada and 1 more
    Volunteers
    335 people
    Sponsor
    National Cancer Institute (NCI)
  • Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma

    Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

    • Recruiting
    • Age: 18 years and older
    • Phase 1
    • Injection or infusion
    • Surgery or procedure

    This phase I trial tests the safety, side effects, and best dose of combination therapy with liposomal doxorubicin and peposertib in treating patients with sarcoma that has spread from where it first started, to other places in…

    Conditions
    Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma, Metastatic Myxofibrosarcoma, Metastatic Sarcoma
    Trial name
    NCT05711615
    Testing
    Biopsy Procedure, Biospecimen Collection, Computed Tomography
    Where
    16 sites in United States
    Volunteers
    30 people
    Sponsor
    National Cancer Institute (NCI)
  • Core Binding Factor Acute Myeloid Leukemia

    Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

    • Recruiting
    • Age: 18 to 59 years
    • Phase 2
    • Pill or oral medicine
    • Injection or infusion

    This phase II MYELOMATCH treatment trial compares the effect of venetoclax to gemtuzumab ozogamicin, when given with cytarabine and daunorubicin ("7+3" regimen), for the treatment of patients with core binding factor acute…

    Trial name
    NCT06917911
    Testing
    Biospecimen Collection, Bone Marrow Aspiration, Cytarabine
    Where
    81 sites in United States, Puerto Rico
    Volunteers
    162 people
    Sponsor
    National Cancer Institute (NCI)
  • Recurrent Ganglioneuroblastoma, Recurrent Neuroblastoma

    Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse

    • Recruiting
    • Age: 1 year to 30 years
    • Phase 1/2
    • Injection or infusion
    • Surgery or procedure

    This phase I/II trial studies the side effects and best dose of iberdomide when given together with chemoimmunotherapy drugs and to see how well it works in treating patients with neuroblastoma that has come back after a period…

    Conditions
    Recurrent Ganglioneuroblastoma, Recurrent Neuroblastoma, Refractory Ganglioneuroblastoma, Refractory Neuroblastoma
    Trial name
    NCT07437963
    Testing
    Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography
    Where
    3 sites in United States
    Volunteers
    76 people
    Sponsor
    National Cancer Institute (NCI)
  • Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma

    Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

    • Recruiting
    • Age: 18 years and older
    • Phase 2
    • Surgery or procedure

    This phase II trial studies how well osimertinib works in treating patients with non-small cell lung cancer with EGFR exon 20 insertion mutation that is stage IIIB-IV or has come back after a period of improvement (recurrent).

    Conditions
    Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
    Trial name
    NCT03191149
    Testing
    Biospecimen Collection, Computed Tomography with Contrast, Echocardiography Test
    Where
    347 sites in United States
    Volunteers
    46 people
    Sponsor
    National Cancer Institute (NCI)
  • Mantle Cell Lymphoma

    Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

    • Recruiting
    • Age: 18 years and older
    • Phase 2
    • Injection or infusion
    • Surgery or procedure

    This phase II trial studies the side effects of acalabrutinib, obinutuzumab, and glofitamab and how well they work together for treating patients with mantle cell lymphoma that has come back after a period of improvement…

    Trial name
    NCT06054776
    Testing
    Acalabrutinib, Biospecimen Collection, Bone Marrow Biopsy
    Where
    United States
    Volunteers
    40 people
    Sponsor
    City of Hope Medical Center
  • Acute Myeloid Leukemia, Myelodysplastic Syndrome

    Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

    • Recruiting
    • Age: 18 years and older
    • Phase 1
    • Pill or oral medicine
    • Surgery or procedure

    This phase I trial tests the safety, side effects, and best dose of SM08502 (cirtuvivint) alone and in combination with ASTX727 in treating patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

    Conditions
    Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome/Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia
    Trial name
    NCT06484062
    Testing
    Biospecimen Collection, Bone Marrow Aspiration, Cirtuvivint
    Where
    23 sites in United States
    Volunteers
    54 people
    Sponsor
    National Cancer Institute (NCI)

Completed, with results posted

All –
  • Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia

    Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement

    • Completed
    • Age: Up to 364 days
    • Phase 2
    • Injection or infusion
    • Surgery or procedure
    • Results posted

    This pilot phase II trial studies the side effects of azacitidine and combination chemotherapy in infants with acute lymphoblastic leukemia and KMT2A gene rearrangement.

    Conditions
    Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia
    Trial name
    NCT02828358
    Testing
    Azacitidine, Biospecimen Collection, Computed Tomography
    Where
    170 sites in United States, Australia and 2 more
    Volunteers
    78 people
    Sponsor
    National Cancer Institute (NCI)
    Can I take part? NCT02828358
  • Acute Lymphoblastic Leukemia, Acute Undifferentiated Leukemia

    Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

    • Completed
    • Age: Up to 1 year
    • Phase 3
    • Injection or infusion
    • Surgery or procedure
    • Results posted

    This phase III trial studies combination chemotherapy with or without lestaurtinib with to see how well they work in treating younger patients with newly diagnosed acute lymphoblastic leukemia.

    Conditions
    Acute Lymphoblastic Leukemia, Acute Undifferentiated Leukemia, Childhood T Acute Lymphoblastic Leukemia
    Trial name
    NCT00557193
    Testing
    Asparaginase, Biospecimen Collection, Bone Marrow Biopsy
    Where
    170 sites in United States, Australia and 2 more
    Volunteers
    218 people
    Sponsor
    Children's Oncology Group
    Can I take part? NCT00557193

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in